RepliCel Life Sciences Management
Management criteria checks 4/4
RepliCel Life Sciences' CEO is Andrew Schutte, appointed in Nov 2022, has a tenure of 2.17 years. total yearly compensation is CA$62.92K, comprised of 76.3% salary and 23.7% bonuses, including company stock and options. directly owns 29.8% of the company’s shares, worth $19.37K. The average tenure of the management team and the board of directors is 2.2 years and 7.5 years respectively.
Key information
Andrew Schutte
Chief executive officer
CA$62.9k
Total compensation
| CEO salary percentage | 76.3% |
| CEO tenure | 2.2yrs |
| CEO ownership | 29.8% |
| Management average tenure | 2.2yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CA$1m |
| Jun 30 2024 | n/a | n/a | CA$763k |
| Mar 31 2024 | n/a | n/a | CA$400k |
| Dec 31 2023 | CA$63k | CA$48k | -CA$312k |
| Sep 30 2023 | n/a | n/a | -CA$69k |
| Jun 30 2023 | n/a | n/a | -CA$366k |
| Mar 31 2023 | n/a | n/a | -CA$919k |
| Dec 31 2022 | CA$9k | n/a | -CA$743k |
| Sep 30 2022 | n/a | n/a | -CA$4m |
| Jun 30 2022 | n/a | n/a | -CA$4m |
| Mar 31 2022 | n/a | n/a | -CA$4m |
| Dec 31 2021 | CA$15k | n/a | -CA$4m |
| Sep 30 2021 | n/a | n/a | -CA$3m |
| Jun 30 2021 | n/a | n/a | -CA$3m |
| Mar 31 2021 | n/a | n/a | -CA$3m |
| Dec 31 2020 | CA$14k | n/a | -CA$2m |
| Sep 30 2020 | n/a | n/a | -CA$2m |
| Jun 30 2020 | n/a | n/a | -CA$2m |
| Mar 31 2020 | n/a | n/a | -CA$3m |
| Dec 31 2019 | CA$12k | n/a | -CA$3m |
| Sep 30 2019 | n/a | n/a | -CA$3m |
| Jun 30 2019 | n/a | n/a | -CA$3m |
| Mar 31 2019 | n/a | n/a | -CA$3m |
| Dec 31 2018 | CA$13k | n/a | -CA$3m |
Compensation vs Market: Andrew's total compensation ($USD43.64K) is below average for companies of similar size in the US market ($USD649.25K).
Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.
CEO
Andrew Schutte (34 yo)
2.2yrs
Tenure
CA$62,917
Compensation
Mr. Andrew Schutte serves as President, Chief Executive Officer & Director of RepliCel Life Sciences Inc. since November 28, 2022. He served as an Independent Director of RepliCel Life Sciences Inc. since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.2yrs | CA$62.92k | 29.8% $ 19.4k | |
| Co-Founder & Chief Scientific Officer | 13.4yrs | CA$72.00k | 2.04% $ 1.3k | |
| Chief Financial Officer | 1.4yrs | CA$40.00k | no data | |
| Chief Legal Officer | 2.2yrs | CA$72.00k | 0.49% $ 320.5 |
2.2yrs
Average Tenure
Experienced Management: REPC.F's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | CA$62.92k | 29.8% $ 19.4k | |
| Independent Chairman of the Board | 14.1yrs | CA$24.00k | 1.8% $ 1.2k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Chairman of Clinical Advisory Board | 11.3yrs | no data | no data | |
| Independent Director | 13.7yrs | CA$17.50k | 1.39% $ 904.4 | |
| Director | 9yrs | CA$11.36k | 0.010% $ 6.8 | |
| Independent Director | 3.6yrs | CA$15.25k | 0.48% $ 314.8 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | 3.7yrs | no data | no data | |
| Senior Strategic Advisor to Directors | 3.3yrs | no data | no data |
7.5yrs
Average Tenure
61.5yo
Average Age
Experienced Board: REPC.F's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:38 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RepliCel Life Sciences Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Echelon Wealth Partners Inc. |